FDA approves Koselugo as first U.S. drug to treat type 1 neurofibromatosis in children
-
Last Update: 2020-05-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The FDA announced Friday (April 10, 2020) that it has approved AstraZeneca and Merck and Merck's Koselugo for the treatment of children with type 1 neurofibromatoma (NF1) ages 2 and older, the first FDA-approved treatment for NF1Specifically, Koselugo is suitable for children with symptomatic, surgically invasive neurofibromatosis"For the first time, pediatric patients have FDA-approved drugs to treat clumps of neurofibromatoma, a rare tumor associated with NF1," said Richard Pazdur, director of the FDA's Center for Oncology Researchthe approval is based on a clinical trial by the U.SNational Cancer Institute in children with NF1 and unsurgical clumps of neurofibromatomaPatients took oral selumetinib twice a day during the 28-day cycle and regularly assessed tumor size and tumor changesThe results showed that the overall remission rate (ORR) was 66% in patients and that all patients had partial remission (PR), of which 82% were for 12 months or more
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
